Canada markets close in 6 hours 14 minutes


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
41.51+0.53 (+1.29%)
As of 9:44AM EST. Market open.
Sign in to post a message.
  • P
    On a CE Zoom meeting tonight with a local Retina group discussing AMD etc......
    Will ask about RGNX/outlook....and competitors liek NVS/Roche with Port delivery systems.
    These port systems seem moot if gene therapy works
    Will report back and buy more on any RetMD feedback who are in the trenches
  • Y
    DIRT CHEAP low float Biotech about to EXLOODEEEE

    (CYTH) MCap $27 M -Shares Out 4 M--Orphan Drug in Phase 3 ($500+ M Potential ) + Alzheimer Drug Phase 2 ready /NEW Nasdaq stock =Next potential 10+ BAGGER

  • P
    Thanks Max for your feedback in an earlier post.
  • C
    Company seems to be making solid progress as mentioned in PR yesterday. RGNX-314 has moved to P3 and they also announced new program RGNX-202 to treat DMD. RGNX-202 seems to be very promising program but it will be several years in the future before we will know how well it is doing. If successful, RGNX can go to over $10 Billion in market cap.
  • M
    I've been waiting 2 years for this to come back...I don't know how much longer I want to wait I'm thinking about cutting my losses and moving into something else to recover.
  • P
    Why is RGNX tanking today?
    Moderate volume tho.
  • s
    New 13G/A filling shows 3 new 5% owners

    GIC Private Limited with 1947189 shares

    The Kiser 2012 Gift Trust LLC with 1,911,890 shares

    Prevail Therapeutics Inc which was bought out by Eli Lilly last December
  • P
    Glad I picked up some shares on that last dip.....
    Just trading action.
    WorldSymposium Feb 8-12
  • S
    Sarepta did a similar move, of issuing secondary offering not once but 3 times...and it kept going up. Hope that trend happens to RGNX as well, except the recent drop of 50%
  • a
    Offering just announced to pressure SP? Any thoughts?
  • S
    Sir Pops
    The RGNX 202 timeline keeps getting extended and market is worried about higher cash burn/more dilution. Frustrating stock.
  • P
    New here, juts heard of this gene technology for eyecare. Trying to understand competitors.
    Seems like ADVM like a direct competitor in the same are of VEGF, seem to both be in phase 2....
    Interested in both companies, but not sure if one is farther along/better pipeline/competitive advantage.
    Thanks in advance.
  • A
    Interesting PR on the sale of $200MM of future Zolgensma royalties at a markup to the lender. No dilution and this demonstrates a lot of confidence in Mr. Mills and the management team with regards to their use of the cash. They must be feeling bullish about the future and I anticipate the stock price to respond accordingly.

    We've had a great ascent in the past 50 days! This news, coupled with the recent UBS upgrade may mean some good stuff is ahead for RGNX and us shareholders. As other licensee partners evolve (RCKT, PRVL, RARE and others), I'm feeling that '21-'22 are looking bright (pun intended) for RegenexBio!
  • B
    I like seeing this slowly and quietly going up on low volume during today's chaos
  • d
    One analyst has PT OF $100
  • J
    here is MHO, N needs us to go to 60 so they can offer us 90-100 per share with out getting major blowback from shareholders of N
  • f
    smart not to do an offering dilluting shares.stock will be paying off in the next year and will be taken out
  • f
    very sleazy of management to do a secondary after selling royalty payment would never buy more of this company stuck with what I have
  • M
    It's good to see Regenxbio steadily climb for a change. Compared to many other bio's (CRSP, EDIT, BEAM, NTLA etc) this hasn't really added too much value over the past months. Is it too much to ask for a similar move in RGNX or does their technique differ too much from the crspr stocks to justify an even bigger jump in market cap?!
  • M
    good article on seeking alpha about RGNX. I didn't write it, but it does encapsulate my feelings on the issue. this is one to hold with confidence and add if the market dips. I think UBS underestimates the potential of this issue even with the 57 price target. Another interesting play in the space is MGTX. both trading well off their all time highs with catalysts on the horizon.